MG1MA3

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameMG1MA3
Drug Alias NameMarabexMG1 Maraba/MAGE-A3MG1-MAGEA3MG1-MA3Ad-MG1 +[6] 
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionNeoplasm antigens modulatorsImmunostimulants
TargetsNeoplasm antigens
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMcmaster UniversityUniversity Of Ottawa Heart InstituteChildren'S Hospital Of Eastern Ontario Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTurnstone Biologics Corp
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A